UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------
FORM 10-Q/A
Amendment No. 3
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 29, 2001
Commission File Number 1-10827
PHARMACEUTICAL RESOURCES, INC.
(Exact name of registrant as specified in its charter)
NEW JERSEY 22-3122182
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
One Ram Ridge Road, Spring Valley, New York 10977
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (845) 425-7100
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding twelve months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes x No_____
32,016,652
Number of shares of Common Stock outstanding as of November 7, 2001
PART II. OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
- ------ --------------------------------
(a) Exhibits:
10.40 License and Supply Agreement, dated as of April 26, 2001, between
Elan Transdermal Technologies, Inc. and Par Pharmaceutical, Inc.*
10.41 Development and Supply Agreement, dated as of April 17, 2001,
between Par Pharmaceutical, Inc., Dr. Reddy's Laboratories
Limited, and Reddy-Cheminor, Inc.*
* Exhibits 10.40 and 10.41 were previously attached to our Quarterly
Report on Form 10-Q for the three months ended September 29, 2001, as amended by
our Form 10-Q/A. Pursuant to a confidential treatment request filed with the
Securities and Exchange Commission, certain portions of Exhibits 10.40 and 10.41
were omitted in our prior filing. The current filing reflects the Securities and
Exchange Commission's decision regarding our confidential treatment request.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHARMACEUTICAL RESOURCES, INC.
------------------------------
Registrant)
July 19, 2002 /s/ Kenneth I. Sawyer
-----------------------------------------
Kenneth I. Sawyer
Chief Executive Officer and Chairman of
the Board of Directors
(Principal Executive Officer)
July 19, 2002 /s/ Dennis J. O'Connor
---------------------------------------
Dennis J. O'Connor
Vice President - Chief Financial Officer
and Secretary
(Principal Accounting and Financial
Officer)